A recent surge in interest in T cell engagers, a type of antibody engineered to redirect the immune system’s T cells to recognize and kill cancer cells, suggests that this field is set to take off. Several biotech companies have launched specifically to develop these medicines, and big names in the industry are investing in…
pharmacy on The Soothsayer / page 2
The biotech industry is witnessing a surge in the development of GPCR (G protein-coupled receptor) therapies, with eight promising biotechs acquiring funding to fortify their pipelines. These biotechs are working on various GPCR-targeted drugs to address numerous diseases, including neuropathic pain, cancer, and metabolic disorders. The market for GPCR drugs is expected to grow significantly,…
Multiple sclerosis is a chronic disease of the central nervous system that affects nearly one million people in the U.S. alone. Biotech companies are working to expand therapeutic options for the disease, which is currently treated with disease-modifying drugs. Several companies, including Biogen, Immunic Therapeutics, Kyverna Therapeutics, Progentos Therapeutics, TG Therapeutics, and Zenas BioPharma, are…
Researchers have made a significant discovery in understanding the molecular pathway behind endometriosis, a painful condition affecting millions of women worldwide. The study suggests that drugs already used to treat migraines could be effective in treating endometriosis by inhibiting a key protein that promotes pain and exacerbates the disease. This breakthrough offers new hope for…
The biopharma industry is in need of talented minds to take promising pipelines to the clinic and beyond. Venture capitalists have nominated prominent founders and entrepreneurs in the biotech industry who are committed to bringing potentially life-changing treatments to market. These entrepreneurs have proven their expertise in hitting milestones, be it in the lab or…
A new wave of biomimicry companies is harnessing the power of nature to develop innovative treatments for various diseases. By studying the properties of plants and animals, these companies are creating novel therapeutic targets and drugs that mimic natural protective mechanisms. From tick saliva to snake venom, these biomimicry companies are unlocking the secrets of…
The biopharma industry is witnessing a surge in investment in the immunology field, with over 10 buyouts of immunology and inflammation (I&I) drug developers this year. Several biotech companies have raised impressive funds to advance the development of their immunology-related research and development (R&D). These companies are working on innovative treatments for various diseases, including…
